Cancer Immunotherapies Market Size in 2022, Impact of COVID-19, Growth, Share, Applications, SWOT analysis, Forecast 2028

Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body’s immune system to attack tumours.Report OverviewDue to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of percent during the forecast period 2022-2028.The USA market for Cancer Immunotherapies is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The China market for Cancer Immunotherapies is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The Europe market for Cancer Immunotherapies is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of percent during the forecast period of 2023 through 2028.The global key manufacturers of Cancer Immunotherapies include Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis and Pfizer, etc. In 2021, the global top five players had a share approximately percent in terms of revenue.